Effect of doxycycline on chronic intermittent hypoxia-induced atrial remodeling in rats
Tóm tắt
Atrial remodeling in the form of fibrosis is considered the basis in the development of atrial fibrillation (AF). The aim of this study was to investigate the effects of doxycycline on atrial remodeling induced by chronic intermittent hypoxia (CIH) and the mechanisms underlying such changes. A total of 45 Sprague-Dawley rats were randomized into three groups: control group, CIH group, CIH with doxycycline treatment (CIH-D) group. A rat model of atrial remodeling was established by CIH and Masson staining was used to evaluate the extent of atrial fibrosis. We studied the expression levels of microRNA-1 (miR-1), microRNA-21 (miR-21), microRNA-29b (miR-29b), microRNA-30 (miR-30), microRNA-133a (miR-133a), microRNA-328 (miR-328), transforming growth factor-β1 (TGF-β1), and connective tissue growth factor (CTGF). Atrial effective refractory period and AF inducibility were examined via isolated heart models of cardiac electrophysiology. Compared with the control rats, CIH rats showed higher atrial interstitial collagen deposition, increased AF inducibility, and increased miR-1, miR-21, miR-133a, miR-328, TGF-β1, and CTGF levels. Treatment with doxycycline significantly attenuated CIH-induced atrial fibrosis, improved AF inducibility, and reduced miR-1, miR-21, miR-133a, miR-328, TGF-β1, and CTGF. CIH induced significant atrial remodeling, which was attenuated by doxycycline in our rat model. These changes can be explained by the alterations initiated in the miR-133a/TGF-β1/CTGF pathway by doxycycline.
Tài liệu tham khảo
Schotten U, Verheule S, Kirchhof P, Goette A (2011) Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 91:265–325. https://doi.org/10.1152/physrev.00031.2009
Jalife J, Kaur K (2015) Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med 25:475–484. https://doi.org/10.1016/j.tcm.2014.12.015
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297. https://doi.org/10.1016/S0092-8674(04)00045-5
Wojciechowska A, Braniewska A, Kozar-Kamińska K (2017) MicroRNA in cardiovascular biology and disease. Adv Clin Exp Med 26:865–874. https://doi.org/10.17219/acem/62915
van den Berg NWE, Kawasaki M, Berger WR (2017) MicroRNas in atrial fibrillation: from expression signatures to functional implications. Cardiovasc Drugs Ther 31:345–365. https://doi.org/10.1007/s10557-017-6736-z
Santulli G, Iaccarino G, De Luca N, Trimarco B, Condorelli G (2014) Atrial fibrillation and microRNAs. Front Physiol 5:15–22. https://doi.org/10.3389/fphys.2014.00015
Hua XF, Li XH, Li MM, Zhang CY, Liu HJ, Sun T et al (2017) Doxycycline attenuates paraquat-induced pulmonary fibrosis by downregulating the TGF-beta signaling pathway. J Thorac Dis 9:4376–4386. https://doi.org/10.21037/jtd.2017.10.42
Hackmann AE, Rubin BG, Sanchez LA, Geraghty PA, Thompson RW, Curci JA (2008) A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg 48:519–526. https://doi.org/10.1016/j.jvs.2008.03.064
Wang W, Zhang K, Li X, Ma Z, Zhang Y, Yuan M, Suo Y et al (2018) Doxycycline attenuates chronic intermittent hypoxia-induced atrial fibrosis in rats. Cardiovasc Ther. https://doi.org/10.1111/1755-5922.12321
Hammond SM (2015) An overview of microRNAs. Adv Drug Deliv Rev 87:3–14. https://doi.org/10.1016/j.addr.2015.05.001
Shi KH, Tao H, Yang JJ, Wu JX, Xu SS, Zhan HY (2013) Role of microRNAs in atrial fibrillation: New insights and perspectives. Cell Signal 25:2079–2084. https://doi.org/10.1016/j.cellsig.2013.06.009
Doñate Puertas R, Jalabert A, Meugnier E, Euthine V, Chevalier P, Rome S (2018) Analysis of the microRNA signature in left atrium from patients with valvular heart disease reveals their implications in atrial fibrillation. PLoS ONE 13:e196666. https://doi.org/10.1371/journal.pone.0196666
van Middendorp LB, Kuiper M, Munts C, Wouters P, Maessen JG, van Nieuwenhoven FA et al (2017) Local microRNA-133a downregulation is associated with hypertrophy in the dyssynchronous heart. Esc Heart Fail 4:241–251. https://doi.org/10.1002/ehf2.12154
Liu Y, Liang Y, Zhang JF, Fu WM (2017) MicroRNA-133 mediates cardiac diseases: Mechanisms and clinical implications. Exp Cell Res 354:65–70. https://doi.org/10.1016/j.yexcr.2017.03.037
Leask A, Holmes A, Abraham DJ (2002) Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 4:136–142. https://doi.org/10.1007/s11926-002-0009-x
Liu Q, Chu H, Ma Y, Wu T, Qian F, Ren X et al (2016) Salvianolic acid B attenuates experimental pulmonary fibrosis through inhibition of the TGF-beta signaling pathway. Sci Rep 6:27610. https://doi.org/10.1038/srep27610
Kim KH, Park GT, Lim YB, Rue SW, Jung JC, Sonn JK et al (2004) Expression of connective tissue growth factor, a biomarker in senescence of human diploidfibroblasts, is up-regulated by transforming growth factor-beta-mediated signaling pathway. Biochem Biophys Res Commun 318:819–825. https://doi.org/10.1016/j.bbrc.2004.04.108
Chen CC, Lau LF (2009) Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 41:771–783. https://doi.org/10.1016/j.biocel.2008.07.025
Kiryu M, Niwano S, Niwano H, Kishihara J, Aoyama Y, Fukaya H et al (2012) Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model. Europace 14:1206–1214. https://doi.org/10.1093/europace/eus052
Xu GJ, Gan TY, Tang BP, Chen ZH, Ailiman M, Zhou XH, Jiang T et al (2013) Changes in microRNAs expression are involved in age-related atrial structural remodeling and atrial fibrillation. Chin Med J (engl) 126:1458–1463
Angelini A, Li Z, Mericskay M, Decaux JF (2015) Regulation of Connective Tissue Growth Factor and Cardiac Fibrosis by an SRF/MicroRNA-133a Axis. PLoS ONE 10:e139858. https://doi.org/10.1371/journal.pone.0139858
Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M et al (2011) Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 4:446–454. https://doi.org/10.1161/CIRCGENETICS.110.958975